SelectScience
Join Free
Accelerating Science
NewsDrug Discovery & Development

Minaris will be the commercial manufacturer in Europe for Skysona, bluebird bio’s gene therapy for CALD

Minaris Regenerative Medicine GmbH
29 Jul 2021
Ellen Simms
Product and Reviews Editor

Industry news

Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for Skysona™ (elivaldogene autotemcel, Lenti-D™), a product of bluebird bio, Inc. The European Commission (EC) has granted marketing authorization for Skysona™, the first and only gene therapy for patients with Early Cerebral Adrenoleukodystrophy (CALD), a life-threatening progressive neurodegenerative disease.

“We are proud to contribute to the fight against this devastating disease in children and to support bluebird bio also with their second commercial product”, said Dusan Kosijer, CEO of Minaris Regenerative Medicine GmbH.

“Minaris is our long-standing partner for bringing gene therapies to patients in Europe,” said Andrew Obenshain, president, severe genetic diseases, bluebird bio. “Our collaboration will be integral as we work to provide Skysona™ to the community who faces the rapid and irreversible effects of CALD.”

In 2016, Minaris and bluebird bio entered into a strategic manufacturing partnership for commercial production of Zynteglo™ for transfusion-dependent β-thalassemia (TDT) and Skysona™ for CALD in Europe. In 2020, the companies expanded their manufacturing partnership to include late stage and commercial drug product manufacturing both in Europe and the USA (at Minaris Regenerative Medicine, LLC) of LentiGlobin™ for the treatment of patients with sickle cell disease (SCD).

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Minaris Regenerative Medicine GmbH

Tags

Combinatorial ChemistryCombinatorial chemistry, also known as combichem, is a technique used in drug discovery to create libraries of structurally related compounds. A library is generated by synthesis with a chemical reactor system or by computer-based modeling of compound combinations. When undertaking combinatorial chemistry consider reagents, buffers, resins and standards.Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Regenerative MedicinePharmaceuticalsPharmaceuticals are medicinal drugs used in healthcare to diagnose, prevent, cure and treat illnesses. Pharmaceuticals that are excreted after use appear in wastewater and can have detrimental effects on the environment.NeurodegenerationNeurodegeneration refers to the progressive deterioration of the structure and function of the nervous system, often seen in diseases like Alzheimer's and Parkinson's. Research focuses on early detection and potential therapies. Explore neurodegeneration research tools in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Gene TherapyGene therapy is a technique that modifies or replaces genes within an individual's cells to treat or prevent diseases. This approach holds potential for curing genetic disorders, cancers, and certain viral infections. Advances in gene editing technologies like CRISPR are driving the growth of gene therapy. Explore gene therapy tools and technologies in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.

Related articles